Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 1998

View Archived Issues

Cytokine-suppressive antiinflammatory drugs from SKB

StressGen updates shareholders

Selective dopamine D3 receptor ligands developed at Neurogen

OraVax: Q1 1998 highlights

Penford approves spin-off of pharmaceutical business

Fuisz's EA technology improves onset of action of pain drugs

Neoprobe's ACT shows activity against HIV/AIDS in preclinical studies

Investigators discover clues to the functions of apoE

New antioxidants from Warner-Lambert

Renal effects of BG-9719 demonstrated in CHF patients and healthy volunteers

Glaxo Wellcome to distribute Cortecs' Macritonin in Greece

MDX-210 shows significant antitumor activity in prostate and kidney cancer patients

Forest's antidepressant drug is approvable

Preclinical efficacy in multiple gastrointestinal disorders reported for ALX-0600

Gd-Tex phase Ib/II interim results presented at ASCO

Icos begins phase I/II trial for antipsoriatic

TGF-beta3 proves ineffective for the treatment of oral mucositis

Long-term prevention of precancerous colonic polyp formation demonstrated for FGN-1

VUF-5087, a structurally rigid CysLT1 receptor antagonist

Eisai seeks collaborators for development of novel antipsychotic

Techniclone evaluates VEGF as a tumor marker

U.S. market introduction announced for Plavix

Fibrinogen receptor antagonists claimed by DuPont Merck

Sankyo prepares neuraminic acid compounds useful for preventing the flu

Thienopyridines for impotence, heart failure in development at Merck KGaA

Safety profile of ISIS-2302 in renal transplant patients

Results from phase II trial of Campylobacter vaccine

Nicaraven shows promise for protecting liver transplants

Capecitabine clinical data and product introduction announced at ASCO

Improved immunosuppression and synergistic effects described for malononitrilamides

BLA and MAA filed for recombinant factor VIII product for hemophilia A

Molecular Biosystems: Q4 and FY 1997 highlights

FDA approves Aggrastat, the first platelet blocker for unstable angina

Suradista, a novel distamycin derivative in phase I testing at Pharmacia & Upjohn

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...